× Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our privacy policy



meta|Evidence breast cancer

Living evidence synthesis
about last generation of breast cancer treatment

Member of the meta|Evidence galaxy

Latest studies

Li, 2024

breast cancer - triple negative

camrelizumab plus SOC

KEYNOTE-119 PD-L1 positive (CPS = 1 or more), 2019

la/mBC - TNBC - L2 - PDL1 positive

pembrolizumab alone

KEYNOTE-119 PD-L1 positive (CPS = 10 or more), 2019

la/mBC - TNBC - L2 - PDL1 positive

pembrolizumab alone

IMpassion-132, PD-L1 positive population, 2024

la/mBC - TNBC - L2 - PDL1 positive

atezolizumab plus SoC

A-Brave Stratum A, 2024

es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)

avelumab alone

NeoTrip Michel Angelo, 2022

es-BC - TNBC - NA - all population

atezolizumab plus SoC

TORCHLIGHT PDL 1 positive population, 2024

la/mBC - TNBC - L1 - PDL1 positive

nab-paclitaxel plus toripalimab

TORCHLIGHT, 2024

la/mBC - TNBC - L1 - all population

nab-paclitaxel plus toripalimab

ICON, 2024

la/mBC - HR positive - L2 - all population

nivolumab plus ipilimumab

Saphir02 Breast-Immuno, 2021

mBC - HER 2 negative

durvalumab alone

ATEMPT, 2021

breast cancer - adjuvant

trastuzumab emtasine plus endocrine therapy

Bachelot, 2022

breast cancer - adjuvant

everolimus

DESTINY-Breast04, 2022

metastatic/advanced - breast cancer (mBC)

trastuzumab deruxtecan

NCT00454805, 2013

la/mBC - HR-positive - 1st line (L1)

cediranib plus fulvestrant

NEO-ORB (mutant cohort), 2019

la/mBC - HR positive - (neo)adjuvant (NA)

alpelisib plus letrozole

NCT02756364 (sapanisertib weekly), 2022

la/mBC - HR-positive - 2nd line (L2)

sapanisertib plus fulvestrant

NEO-ORB (buparlisib vs placebo), 2019

la/mBC - HR positive - (neo)adjuvant (NA)

buparlisib plus letrozole

SYSUCC-002, 2022

la/mBC - HER2 positive - 1st Line (L1)

trastuzumab plus endocrine therapy

KCSG-BR15-10, 2019

la/mBC - HR positive

palbociclib plus endocrine therapy

REACT, 2021

la/mBC - HR-positive - 2nd line (L2)

celecoxib plus endocrine therapy

457
treatments 		  384
studies 		  1296
references
This project is supported by H2020 Qualitop, an EU-funded project, Hospices Civils de Lyon and CNRS UMR5558 LBBE.
     

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons